| PANDEMIC ALERT LEVEL |
| 123456 |
| Mpox Discussion Forum: Latest News & Information Regarding the Clade 1b Mpox Virus |
Post Reply - On M-pox |
| Post Reply |
| Message |
| Topic - On M-pox Posted: 14 Jul 2024 at 9:52am By Dutch Josh |
|
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00187-6/fulltext#%20 or https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00187-6/fulltext#%20 ;
Mpox was previously thought to be a zoonotic disease endemic in parts of central, west, and east Africa; however, from 2022 to 2023, a large global outbreak of mpox from clade II monkeypox virus occurred, marking the first instance of sustained transmission outside of Africa since the first case of mpox in a human was identified in 1970. More recently, clade I monkeypox virus has been responsible for a growing outbreak in the Democratic Republic of the Congo, with evidence of sexual transmission suggesting the potential for global spread. The increasing burden of endemic African mpox, geographic expansion into previously unaffected areas, novel transmission via sexual contact, rising case fatality rates in rural areas, and transmission in urban areas raise serious health concerns, but African researchers still struggle to obtain funding to study this disease. The 2022–23 global mpox outbreak occurred despite repeated warnings from African researchers and calls for investment into diagnostic, therapeutic, and infection prevention tools. Swift public health responses and a notable increase in mpox research occurred almost entirely among high-income countries in Europe and North America. Given the substantial global reduction in mpox cases following the international response and the ongoing outbreaks and changing disease epidemiology in the Democratic Republic of the Congo, research to better understand mpox epidemiology, prevention, and treatment should be prioritised in Africa., - We have proposed the establishment of an African-led, multidisciplinary, multicountry Mpox Research Consortium (MpoxReC) in Africa with an overarching goal of establishing a research network to advance the elimination of mpox as a public health problem (with an initial focus on Cameroon, the Central African Republic, the Democratic Republic of the Congo, Ghana, Nigeria, and the Republic of the Congo). MpoxReC will integrate basic research; clinical studies; disease surveillance; risk communication; community engagement; phylogeographic, ecological, and anthropologic studies; novel studies for use of medical countermeasures; and capacity building to address mpox epidemics and ultimately eliminate its human-to-human transmission (appendix p 1). Names of principal investigators and collaborating institutions, organisations, and investigators are available in the appendix (pp 2–3). The MpoxReC regional research agenda was presented and endorsed at the first high-level international meeting on mpox in Kinshasa, the Democratic Republic of the Congo, in April, 2024. DJ, Start with the source of the problem. Keeping countries poor means a lot of health crises...If you have one "doctor" per 100,000+ people forget about detection of health risks in time ! The latest mpox outbreaks in Africa require urgent collaborative efforts to address the evolving epidemiology and transmission dynamics of the disease. MpoxReC aims to establish a multidisciplinary research network to generate knowledge, strengthen surveillance, and enhance African public health responses. DJ; Vaccines-at best-can be part of a solution ! Better education, surveilance, in time detection of diseases (not only Mpox) is needed. Besides that-why did Mpox "get a problem in the west" ? CoViD related ?
|
